The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

is that C. difficile is evolving to resist vancomycin. "We don't know if there are resistant strains circulating and causing ...

With no approved vaccines to date, C. diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

Pfizer has been working on a potential vaccine for C. diff, but its first attempt missed ... updated formulation through mid-stage clinical testing. In the phase 3 ECOSPOR trial, patients who ...

The study, published Sept. 30 in Open Forum Infectious Diseases, analyzed 45,049 patient records from 779 hospitals of adults who received treatment for C. diff infections before and after 2021.

The C-peptide test helps your doctor identify whether you have type 1 diabetes (when the immune system attacks and destroys cells in the pancreas) or type 2 diabetes (when your body doesn't use ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

An advantage of CRS3123 compared with other treatments is its narrow spectrum, which targets C. difficile bacteria and stops toxin production while minimally affecting other microbes in the gut.